Safety Concerns About Saltz Regimen Were Statistical Artifact, ODAC Finds.
AACI: von Eschenbach “Wonderful Choice” For NCI Director, Knows How Centers Work. Cancer Centers Pleased With Bush Choice For NCI.
Campus-Dweller Rabson Finds Comfort In NIH Security.
Endostatin Enters Phase II Trial For Neuroendocrine Tumors.
Siemens To Provide Technology To DxTx For Lung Cancer Detection.
Myriad In Partnership To Market Products.
Computer-Aided Detection Approved For Mammograms.
Trending Stories
- The story of daraxonrasib is the ultimate hero’s journey
A narrative curve with twists, turns, intrigue, drama—and a blow to a mighty foe - As his Senate testimony alleged danger from mRNA COVID vaccine, El-Deiry had an offer to run NCI Frederick lab
The job offer to run the lab—home to virus research, RAS Initiative, and data science—was quickly rescinded - Pancreatic cancer breakthrough came from smart scientists making smart bets—not from politicization of science
- At Senate hearing, Brown’s El-Deiry and other witnesses say they were targeted for arguing that mRNA vaccine may be linked to cancer
- Pancreatic cancer finally starts to budge as daraxonrasib doubles overall survival
- Proposed OMB rule aims at the heart of the U.S. research enterprise—and scientists are fighting back
“The question isn’t whether politics will influence research. Under this proposal, that’s the point. That’s their goal.”
